Roberto Pazo-Cid - Concepedia

Author

Roberto Pazo-Cid

Hospital Universitario Miguel Servet ORCID

Also Known As

Joon Oh Park, Paula Gomila Pons, R. A. Pazo Cid, R. A. Pazo-Cid, R. Pazo, R. Pazo Cid, R. Pazo-Cid, R.A. Pazo Cid, R.A. Pazo-Cid, Robert A. Pazo Cid

128

Publications

8.9K

Citations

H-Index

Concepts

All Affiliations

Hospital Universitario Miguel Servet National Cancer Center Hospital East The University of Texas MD Anderson Cancer Center Sun Yat-sen University Vall d'Hebron Hospital Universitari

About

Roberto Pazo-Cid is an author at Hospital Universitario Miguel Servet specializing in medicine, radiation oncology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	17	20	6K
2	Health Sciences	5	5	640
3	Public Health	1	1	42
4	Biomedical Engineering	1	1	24
5	Epidemiology	1	1	42

Roberto Pazo-Cid

Publications

8.3K

Citations

H-Index

Page 1

	Year	Citations
First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial Yelena Y. Janjigian, Kohei Shitara, Markus Moehler, The Lancet Chemotherapy Versus ChemotherapyEsophageal CancerGastrointestinal OncologyMedicineCheckmate 649	2021	2.7K
Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial Kohei Shitara, Mustafa Özgüroğlu, Yung‐Jue Bang, The Lancet Pembrolizumab Versus PaclitaxelGastrointestinal OncologyMedicineGastroenterologySurgery	2018	1.3K
Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial Kohei Shitara, Florian Lordick, Yung‐Jue Bang, The Lancet OncologyEsophageal CancerGastrointestinal OncologyGastro-oesophageal Junction AdenocarcinomaGastroenterology	2023	609
Epigenetic profiling to classify cancer of unknown primary: a multicentre, retrospective analysis Sebastián Morán, Anna Martínez‐Cardús, Sergi Sayols, The Lancet Oncology OncologyTumor HeterogeneityUnknown PrimaryMedicineEpigenetic Change	2016	497
Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer Kohei Shitara, Jaffer A. Ajani, Markus Moehler, Nature	2022	415
NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial Zev A. Wainberg, Davide Melisi, Teresa Macarulla, The Lancet	2023	374
Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized Phase III Study Lin Shen, Ken Kato, Sung‐Bae Kim, Journal of Clinical Oncology	2022	293
Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label phase 2 study Philip A. Philip, Jill Lacy, Fabienne Portales, The Lancet. Gastroenterology & hepatology Open-label Phase 2Pancreatic CancerGastrointestinal OncologyMedicinePharmacology	2020	227
Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study James J. Harding, Jia Fan, Do‐Youn Oh, The Lancet Oncology MedicineBiliary CancerPathologyPharmacotherapyCancer Treatment	2023	201
Level of <i>HER2</i> Gene Amplification Predicts Response and Overall Survival in HER2-Positive Advanced Gastric Cancer Treated With Trastuzumab Carlos Gómez-Martín, Carlos Plaza, Roberto Pazo-Cid, Journal of Clinical Oncology	2013	195

Page 1